| Autor: |
Torrezan GT; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil.; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil., de Almeida FGDSR; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., Figueiredo MCP; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., Barros BDF; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., de Paula CAA; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., Valieris R; Laboratory of Bioinformatics and Computational Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., de Souza JES; Instituto de Bioinformática e Biotecnologia-2bio, Natal, Brazil.; Instituto Metrópole Digital, Federal University of Rio Grande do Norte, Natal, Brazil.; Bioinformatics Multidisciplinary Environment, Federal University of Rio Grande do Norte, Natal, Brazil., Ramalho RF; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., da Silva FCC; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil., Ferreira EN; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil.; Research and Development, Fleury Group, São Paulo, Brazil., de Nóbrega AF; Oncogenetics Department, A.C. Camargo Cancer Center, São Paulo, Brazil., Felicio PS; Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil., Achatz MI; Oncogenetics Department, A.C. Camargo Cancer Center, São Paulo, Brazil.; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States., de Souza SJ; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil.; Bioinformatics Multidisciplinary Environment, Federal University of Rio Grande do Norte, Natal, Brazil.; Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil., Palmero EI; Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil., Carraro DM; Laboratory of Genomics and Molecular Biology, International Research Center, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil.; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, São Paulo, Brazil. |
| Abstrakt: |
Pathogenic variants in known breast cancer (BC) predisposing genes explain only about 30% of Hereditary Breast Cancer (HBC) cases, whereas the underlying genetic factors for most families remain unknown. Here, we used whole-exome sequencing (WES) to identify genetic variants associated to HBC in 17 patients of Brazil with familial BC and negative for causal variants in major BC risk genes ( BRCA1/2, TP53 , and CHEK2 c.1100delC). First, we searched for rare variants in 27 known HBC genes and identified two patients harboring truncating pathogenic variants in ATM and BARD1 . For the remaining 15 negative patients, we found a substantial vast number of rare genetic variants. Thus, for selecting the most promising variants we used functional-based variant prioritization, followed by NGS validation, analysis in a control group, cosegregation analysis in one family and comparison with previous WES studies, shrinking our list to 23 novel BC candidate genes, which were evaluated in an independent cohort of 42 high-risk BC patients. Rare and possibly damaging variants were identified in 12 candidate genes in this cohort, including variants in DNA repair genes ( ERCC1 and SXL4 ) and other cancer-related genes ( NOTCH2, ERBB2, MST1R , and RAF1 ). Overall, this is the first WES study applied for identifying novel genes associated to HBC in Brazilian patients, in which we provide a set of putative BC predisposing genes. We also underpin the value of using WES for assessing the complex landscape of HBC susceptibility, especially in less characterized populations. |
